These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

39 related items for PubMed ID: 15192923

  • 1. An RCT into calculating insulin start dose in type 2 diabetes.
    Jarvis J, Burden A, Burden ML.
    Nurs Times; ; 100(21):40-4. PubMed ID: 15192923
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service.
    Tahrani AA, Digwood S, Lee C, Moulik P.
    Int J Clin Pract; 2007 Feb; 61(2):329-35. PubMed ID: 17263721
    [Abstract] [Full Text] [Related]

  • 3. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 4. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial.
    Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ, Metformin Trial Group.
    Diabet Med; 2005 May; 22(5):634-40. PubMed ID: 15842521
    [Abstract] [Full Text] [Related]

  • 5. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 6. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 7. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 8. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [Abstract] [Full Text] [Related]

  • 9. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [Abstract] [Full Text] [Related]

  • 10. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [Abstract] [Full Text] [Related]

  • 11. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
    Rowe R, Cowx M, Poole C, McEwan P, Morgan C, Walker M.
    Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [Abstract] [Full Text] [Related]

  • 13. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study.
    Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI.
    Diabet Med; 2005 Mar; 22(3):316-22. PubMed ID: 15717881
    [Abstract] [Full Text] [Related]

  • 14. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

  • 15. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
    Hausmann M, Dellweg S, Osborn C, Heinemann L, Buchwald A, Rosskamp R, Genova P, Heise T.
    Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
    [Abstract] [Full Text] [Related]

  • 16. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
    Bradley C, Gilbride CJ.
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157
    [Abstract] [Full Text] [Related]

  • 17. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 18. Type 2 diabetes mellitus--guidelines for initiating insulin therapy.
    Yeap BB.
    Aust Fam Physician; 2007 Jul; 36(7):549-53. PubMed ID: 17619673
    [Abstract] [Full Text] [Related]

  • 19. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.
    Moses RG, Bartley P, Lunt H, O'Brien RC, Donnelly T, Gall MA, Vesterager A, Wollmer P, Roberts A.
    Diabet Med; 2009 Mar; 26(3):260-7. PubMed ID: 19317821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 2.